Chief Executive Officer and Chairman of the Board of Directors of Pharmacyclics, Mr. Duggan has been a member of the Board of Directors since September 2007. He served as Chairman of the Board of Directors of Computer Motion, Inc., a computerized surgical systems company, from 1990 to 2003 and Chief Executive Officer from 1997. Computer Motion was acquired by Intuitive Surgical, Inc. in 2003. Mr. Duggan is the Founder of the investment firm Robert W. Duggan & Associates. Mr. Duggan has been a private venture investor for more than 30 years and has participated as a director of, investor in and advisor to numerous small and large businesses in the medical equipment, computer local and wide area network, PC hardware and software distribution, digital encryption, consumer retail goods and outdoor media communication industries. Mr. Duggan has also assisted in corporate planning, capital formation and management for his various investments. He received the Congressman’s Medal of Merit and in 2000 he was named a Knight of the Legion of Honor by President Jacques Chirac. Mr. Duggan is currently also a director of Intuitive Surgical, Inc. He is a member of the University of California at Santa Barbara Foundation Board of Trustees.

Maky Zanganeh joined Pharmacyclics in August 2008. From September 2003 to August 2008, Dr. Zanganeh served as Vice President of Business Development for Robert Duggan & Associates. While working with Mr. Duggan, she accepted a position as Director General (2007-2008) for the French government initiative biocluster project in France. Prior to joining Duggan & Associates, Dr. Zanganeh was worldwide Vice President of Training & Education (2002-2003) and President Director General for Europe, Middle east and Africa (1998 - 2002) for Computer Motion Inc., the world initiator of medical robotics. Dr. Zanganeh received a DDS degree from Louis Pasteur University in Strasbourg, France and MBA from Schiller International University in France. She is fluent in French, German, Persian & English.

Dr. Lori Anne Kunkel spent ten years in academic/clinical medicine and served as a faculty member in the Division of Hematology/Oncology Bone Marrow transplant unit at University of California, Los Angeles prior to joining the international biotechnology industry in 1995. Since then, she has held executive positions in a variety of companies that have provided her extensive experience in developing and commercializing oncologic/immunologic therapies. Her areas of responsibilities have included clinical, regulatory, medical affairs and licensing. She has worked for large biotechnology corporations (Genentech/Roche, Chiron/Novartis), and has served as Chief Medical Officer in start-up biotechs (ACT biotech, Syndax, Proteolix (acquired by Onyx) and Clinical Vice President at Genitope and Xencor. She has led US INDs, been directly involved in multiple EU and US strategic regulatory meetings, and secured Orphan Drug designations, Special Protocol Assessments, and Scientific Advice on numerous agents. Most recently she has been the principal of D2D, LLC, a consulting company that she founded. She has participated as a strategic clinical advisor and consultant to several corporations including Aton (acquired by Merck), DNAX (Schering Plough), Salmedix/Cephalon, Zymogenetics, Onyx, Raven, and Xoma, as well as a consultant for Boston and Bay area Venture Capital firms. Dr. Kunkel holds a Bachelor of Arts in Biology from University of California, San Diego; a medical degree from University of Southern California. She is board certified in Internal Medicine and Oncology.

David Loury joined Pharmacyclics as Vice President, Preclinical Sciences in May 2006 with 20 years of pharmaceutical industry experience. Most recently Dr. Loury served at Celera Genomics as Senior Director of Toxicology from April 2003 to April 2006. Prior to that, Dr Loury directed Drug Disposition, and Toxicology at Essential Therapeutics and IntraBiotics Pharmaceuticals from January 1996 to May 2001. Dr. Loury has held positions of increasing responsibility in Preclinical Safety at Syntex Corporation and Roche Pharmaceuticals. He is a Diplomate of the American Board of Toxicology. Dr. Loury received a B.S. degree in Environmental Toxicology and a Ph.D. in Pharmacology and Toxicology from the University of California, Davis.

Dr. Hedrick is a board-certified medical oncologist who received his medical degree from the University Of Maryland School Of Medicine. He served as resident and chief resident in Internal Medicine at Boston City Hospital, and completed a fellowship in Medi­cal Oncology and Hematology at the Memorial Sloan-Kettering Cancer Center. Following completion of his fellowship, he joined the attending staff of the Hematology and Lymphoma Services at Memorial Sloan-Kettering Cancer Center, with a focus on clinical research in non-Hodgkin’s lymphoma, myelodysplastic syndromes, multiple myeloma, and he­matopoietic growth factors. Eric joined Genentech in 2000, where, over a period of nine years, he was responsible for multiple aspects of the drug development and post-marketing programs for Rituximab (Rituxan®) and Bevacizumab (Avastin™). As a Group Medical Director, he oversaw the development of Avastin in GI cancers and in liquid tumors. Since leaving Genentech in September 2009, Eric has among other things, served as a consultant with us on the devel­opment of PCI-32765.

Mr. Erdtmann began his career in Europe as an investment banker. He was accepted into the Investment Banking Program of Commerzbank in Germany after he graduated with distinction from the Westfaelische Wilhelms Universitaet in Muenster, majoring in Financing and Banking. He was later recruited by the asset management arm of Commerzbank and became a portfolio manager for international clients. The portfolio assets under management exceeded $1Billion Dollars. In 1994 he co- founded a German-based real estate company, United Properties Immobilien & Anlagen GmbH, which to date has successfully developed over 30 different projects and manages a portfolio of over 250 units. His main area of responsibility has been setting up the organization and overseeing the financial aspects of its operations. Mr. Erdtmann came to the US in the mid- nineties to manage the assets for a US equity pool and several European investors. He became actively involved in some of the holding companies and served on several of their boards. Building on his European network, he has since consulted high net-worth individuals and closed-end funds, and actively advised in the selection of US investments for over $500 Million. Furthermore he finalized over $120 Million of equity and debt transactions for private equity partnerships.

Gregory Hemmi has served as Vice President, Chemical Operations since May 2006. Dr. Hemmi served as Senior Director, Chemical Development from January 2001 to April 2006 and as Director, Chemical Development from December 1997 to December 2000. Other positions held at Pharmacyclics include Group Leader, Chemical Development from May 1995 to November 1997 and Scientist from June 1992 to April 1995. After graduating with a B.S. in Chemistry, Dr. Hemmi received a Ph.D. from the University of Texas at Austin under the direction of Professor Jonathan L. Sessler.

Joseph J. Buggy has served as Vice President, Research since September 2007. From May 2006 to August 2007, Dr. Buggy served as Senior Director, Cancer Biology. From November 2001 to April 2006, he served as Director, Department of Biology at Celera Genomics, a biotechnology company. From June 1996 to October 2001, he was a staff scientist at AXYS Pharmaceuticals, Inc., a biotechnology company. Prior to that Dr. Buggy worked as a scientist at Bayer Corporation in West Haven, CT. Dr. Buggy received a Ph.D. in Molecular, Cellular, and Developmental Biology from Indiana University and a B.S. degree in Microbiology from the University of Pittsburgh.

Mark Asbury joined Pharmacyclics as Vice President and General Counsel in July 2011 with 15 years of pharmaceutical industry experience. Prior to joining the company, Mr. Asbury held increasingly senior positions in the legal department of Genentech, most recently serving as Associate General Counsel and Senior Director of Transactional Law. In this capacity, he led a group of twelve lawyers, and was responsible for all of Genentech's strategic agreements and partnerships, including research, development and commercial intellectual property licensing agreements, mergers and acquisitions, as well as real estate and construction matters. During his time at Genentech, he oversaw Genentech's environmental health and safety practice, supported the commercial lytics franchise, and was responsible for company-wide contract management processes and initiatives. Prior to joining Genentech, Mr. Asbury was a corporate associate for four years with the law firm of Shearman and Sterling, with experience in securities, M&A and commercial banking transactions. He received his BA in Soviet Studies from Vanderbilt University, and his JD from Stanford University.

Christine Huh joined Pharmacyclics in November 2011. She started her career in the biotechnology industry at Agouron Pharmaceuticals (Pfizer) in 1989. Prior to joining Pharmacyclics, she held numerous Human Resources leadership positions. Most recently, she led Human Resources at InQuira (Oracle), a software company. In 2008, she built and led Human Resources function at Molecular Insight Pharmaceuticals as their Vice President, Human Resources. During her tenure at Myogen (Gilead), she contributed to building and transforming the company from a development stage to a commercial organization, expanding the employee base from 60 to over 160. She also held Human Resources leadership positions at Centaur Pharmaceuticals from 1993 to 2002. Christine received a BS in Psychology from University of California, Davis.

Maria Fardis has served as Vice President, alliance and global project management since December 2011. Dr. Fardis joined Pharmacyclics in April 2011 as Senior Director of Global Project Management. Prior to joining the company, Dr. Fardis held increasingly senior positions in the project and portfolio management department at Gilead. She managed projects in antiviral, oncology, and cardiovascular therapeutic areas while at Gilead. Prior to joining the project and portfolio management, Dr. Fardis worked as a senior scientist in medicinal chemistry in Gilead, Intrabiotics, and Kosan Biosciences. She received her Ph.D. in Organic Chemistry from U. C. Berkeley. Dr. Fardis received her Bachelor of Science degree from University of Illinois, Urbana- Champaign.

Cynthia Anderson joined Pharmacyclics as Vice President, Clinical Operations, in December 2011 with over 20 years pharmaceutical and biotechnology experience in oncology, cardiology, rare genetic disorders, neurology, infectious disease and urology. She served as Vice President at Proteolix (acquired by Onyx) where she successfully collaborated with Dr. Kunkel to build a high performing operations team. She has lead multidisciplinary global teams at Syntex, Roche, BioMarin, Corgentech, Anesiva and Genitope, and was a consultant to over 15 companies. Ms. Anderson has been directly involved with successful NDA and BLA filings resulting in approval. She pursued academic studies at the University of Wisconsin and obtained a Bachelors of Science in Nursing from the University of Arizona.